| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/26/2004 | CA2514649A1 Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders |
| 08/26/2004 | CA2514382A1 Pyrazoles and methods of making and using the same |
| 08/26/2004 | CA2514363A1 Substituted azole derivatives as therapeutic agents |
| 08/26/2004 | CA2513920A1 Application of 2-cyano-10- (2-methyl-3-(methylamino)- propyl)phenothiazine or a pharmaceutically acceptable salt as medicament |
| 08/26/2004 | CA2513837A1 Crystalline forms of pitavastatin calcium |
| 08/26/2004 | CA2513716A1 Piperazine-2-carboxamide derivatives |
| 08/26/2004 | CA2513668A1 Dyrks as modifiers of the apc and axin pathways and methods of use |
| 08/26/2004 | CA2513220A1 Benzamide derivatives as oxytocin agonists and vasopressin antagonists |
| 08/26/2004 | CA2512989A1 Screening and treatment methods for prevention of preterm delivery |
| 08/26/2004 | CA2512934A1 Short immunomodulatory oligonucleotides |
| 08/26/2004 | CA2512757A1 Compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions |
| 08/26/2004 | CA2511900A1 Cetylpyridinium salt of an anti-inflammatory agent and pharmaceutical compositions containing it |
| 08/26/2004 | CA2488143A1 Methods and compositions for modulating glutamate transport activity in the nervous system |
| 08/25/2004 | EP1449922A2 Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis |
| 08/25/2004 | EP1449920A1 Non-human transgenic mammals used as models for human pathologies originating from stem cells |
| 08/25/2004 | EP1449844A1 benzamide derivatives as oxytocin agonists and vasopressin antagonists |
| 08/25/2004 | EP1449843A1 Intermediates for the preparation of carbamoyl tetrahydropyridine derivatives |
| 08/25/2004 | EP1449842A1 Process for the preparation of pyrazolopyridine tartrates |
| 08/25/2004 | EP1449835A2 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds |
| 08/25/2004 | EP1449834A2 Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| 08/25/2004 | EP1449828A2 Guanidinomethyl cyclohexane carboxylic acid ester derivatives |
| 08/25/2004 | EP1449545A1 Medical devices comprising rapamycin |
| 08/25/2004 | EP1449541A1 Compositions inhibiting rejection in organ transplantation and method of using the same |
| 08/25/2004 | EP1449540A1 Cytokine-inducing material and cytokine-inducing instrument |
| 08/25/2004 | EP1449533A1 Use of PVP-iodine liposomes for the treatment of acne |
| 08/25/2004 | EP1449531A2 Melt-extruded orally administrable opioid formulations |
| 08/25/2004 | EP1449530A2 Melt-extruded orally administrable opioid formulations |
| 08/25/2004 | EP1449529A1 Protein Kinase C Inhibitors |
| 08/25/2004 | EP1449528A1 Treatment of respiratory diseases |
| 08/25/2004 | EP1449527A2 Transdermal patch for administering a volatile liquid drug |
| 08/25/2004 | EP1449524A1 Methods and devices for providing prolonged drug therapy |
| 08/25/2004 | EP1449522A1 A free radical quenching liposomal composition |
| 08/25/2004 | EP1449521A1 Use of PVP-iodine liposomes for treatment of atopic dermatitis |
| 08/25/2004 | EP1449520A1 Use of PVP-Iodine liposomes for treatment of herpes |
| 08/25/2004 | EP1449519A1 Liquid composition containing a guanidine amide group derivative and/or a salt thereof |
| 08/25/2004 | EP1449518A1 Use of N-Octanoylaminoacids as cosmetic and pharmaceutical slimming agents |
| 08/25/2004 | EP1449517A1 Use of N-Lauroylaminoacids as cosmetic and pharmaceutical slimming agents |
| 08/25/2004 | EP1449515A1 Anti-acne agents |
| 08/25/2004 | EP1449511A1 Use of Idebenone for the preservation of compositions |
| 08/25/2004 | EP1449435A1 Anthelmintic composition |
| 08/25/2004 | EP1448995A1 Assay for screening candidate drugs for the treatment of inflammatory diseases |
| 08/25/2004 | EP1448986A2 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 08/25/2004 | EP1448771A1 A method for combined parallel agent delivery and electroporation for cell structures and use thereof |
| 08/25/2004 | EP1448770A1 A method for combined sequential agent delivery and electroporation for cell structures and use thereof |
| 08/25/2004 | EP1448753A2 Conditioning solution for contact lenses |
| 08/25/2004 | EP1448592A1 Steroidal compounds for inhibiting steroid sulphatase |
| 08/25/2004 | EP1448591A1 17alpha-alkyl-17beta-oxy-estratrienes and intermediates for the production thereof, and use of said 17alpha-alkyl-17beta-oxy-estratrienes for producing medicaments and pharmaceutical preparations |
| 08/25/2004 | EP1448588A2 Psma antibodies and protein multimers |
| 08/25/2004 | EP1448586A2 Therapeutic methods for nucleic acid delivery vehicles |
| 08/25/2004 | EP1448567A1 Method for the preparation of hexahydro-furo 2,3-b]furan-3-ol |
| 08/25/2004 | EP1448566A2 Chemokine receptor antagonists and methods of use thereof |
| 08/25/2004 | EP1448565A1 ADENOSINE A?2a? RECEPTOR ANTAGONISTS |
| 08/25/2004 | EP1448564A2 Substituted indolizine-like compounds and methods of use |
| 08/25/2004 | EP1448562A1 Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors |
| 08/25/2004 | EP1448561A1 Beta 3 adrenergic agonists |
| 08/25/2004 | EP1448560A1 3-SUBSTITUTED OXINDOLE $g(b)3 AGONISTS |
| 08/25/2004 | EP1448559A1 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient |
| 08/25/2004 | EP1448558A1 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical compositions comprising the same |
| 08/25/2004 | EP1448557A2 Heteroindanes: a new class of potent cannabimimetic ligands |
| 08/25/2004 | EP1448556A1 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
| 08/25/2004 | EP1448554A1 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases |
| 08/25/2004 | EP1448553A1 N-heterocyclyl hydrazides as neurotrophic agents |
| 08/25/2004 | EP1448552A1 Quinoline derivatives, process for preparing them and use for the treatment of diseases mediated by s-cd23 |
| 08/25/2004 | EP1448551A1 Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 08/25/2004 | EP1448550A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity |
| 08/25/2004 | EP1448548A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 08/25/2004 | EP1448547A1 Pyridine derivatives as nmda receptor ligands |
| 08/25/2004 | EP1448546A1 Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake |
| 08/25/2004 | EP1448545A1 Nf-kb inhibitors |
| 08/25/2004 | EP1448544A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 08/25/2004 | EP1448542A1 6-hydroxy isoflavones, derivatives and medicaments involving same |
| 08/25/2004 | EP1448539A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| 08/25/2004 | EP1448537A2 Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| 08/25/2004 | EP1448536A1 Cyclopropyl-containing oxazolidinone antibiotics and derivatives thereof |
| 08/25/2004 | EP1448535A1 Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 08/25/2004 | EP1448534A1 6-membered unsaturated heterocyclic compounds useful for selective inhibition ofthe coagulation cascade |
| 08/25/2004 | EP1448533A1 Dithiocarbamate derivatives and their use as antibacterial agents |
| 08/25/2004 | EP1448531A1 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
| 08/25/2004 | EP1448529A1 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies |
| 08/25/2004 | EP1448528A2 Preparation of pharmaceutical salts of 4((z)-(4-bromophenyl)(ethoxyimino)methyl)-1'-((2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl)-4'-methyl-1,4'bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections |
| 08/25/2004 | EP1448527A1 Method of resolving amlodipine racemate |
| 08/25/2004 | EP1448526A1 Piperidine-based mch antagonists for treatment of obesity and cns disorders |
| 08/25/2004 | EP1448525A1 Novel piperidine derivatives as modulators of chemokine receptors |
| 08/25/2004 | EP1448524A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 08/25/2004 | EP1448523A1 Heterocyclic compounds and methods of use |
| 08/25/2004 | EP1448521A1 Derivatives of andrimide and moiramide b having antibacterial properties |
| 08/25/2004 | EP1448520A1 Benzamide derivatives, processes for their preparation, and their pharmaceutical use |
| 08/25/2004 | EP1448516A1 Hydroxyethylene compounds with asp2 inhibitory activity |
| 08/25/2004 | EP1448515A2 Compounds for treatment of inflammation, diabetes and related disorders |
| 08/25/2004 | EP1448513A1 Biphenyl-derivatives as p38-kinase inhibitors |
| 08/25/2004 | EP1448512A1 Prodrugs of antidepressants and their use for treating depressions |
| 08/25/2004 | EP1448508A1 Double esters |
| 08/25/2004 | EP1448504A2 Clusianon isomers and use thereof |
| 08/25/2004 | EP1448456A1 Transdermal/transmucosal patch packaging |
| 08/25/2004 | EP1448281A2 Therapeutic coating for an intravascular implant |
| 08/25/2004 | EP1448268A2 Use of an farnesyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| 08/25/2004 | EP1448236A1 Inclusion complex of taxol with 2-hxdroxypropyl-beta-cyclodextrin |
| 08/25/2004 | EP1448235A1 Pharmaceutical compositions of 5,7,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene |
| 08/25/2004 | EP1448234A1 Formulations comprising a cephalosporin compound and their use in treating bacterial infections in cats and dogs |
| 08/25/2004 | EP1448233A2 Endothelin antagonists ina method and composition for potentiating an opiate analgesic |